Clinical Trial Update: DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

View source ↗

Summary

The DELFI-L101 study from Delfi Diagnostics, which evaluates DNA fragment analysis for early interception of cancer, has completed enrollment/status. The trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Colorectal Cancer
• Esophageal Cancer
• Head and Neck Cancer
• Liver Cancer
• Lung Cancer
• Pancreatic Cancer
• Stomach Cancer

Snippet

Sponsor: Delfi Diagnostics Inc. | Conditions: Lung Cancer, Head and Neck Cancer | Status: COMPLETED